Nasdaq:US$18.25 (+1.31) | HKEX:HK$29.15 (+0.80) | AIM:£2.87 (+0.11)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Leadership
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Dissemination of Corporate Communications
Modern Slavery and Human Trafficking Statement
Careers
About Us
Overview
Corporate Information
Board of Directors
Leadership
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Dissemination of Corporate Communications
Modern Slavery and Human Trafficking Statement
Careers
Search Result
Chi-Med
Search Result
| 演示文稿
Previous Article
|
Next Article
演示文稿
,
科學出版物
| 29 Sep 2019
ESMO 2019: 索凡替尼用於治療高分化的晚期非胰腺神經內分泌瘤患者的療效和安全性
標題:
索凡替尼用於治療高分化的晚期非胰腺神經內分泌瘤患者的療效和安全性:
隨機化的
III期臨床試驗(SANET-ep)結果
報告人:
中國人民解放軍總醫院第五醫學中心 消化腫瘤科主任 徐建明
摘要編號:
LBA76
日期及時間:
2019年9月29日(星期日),巴塞羅那當地時間(CEST)16:30
報告地點:
Tarragona Auditorium (Hall 7), Fira de Barcelona Gran Via Conference Centre